Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Net Income: 2011-2025

Historic Net Income for Aytu Biopharma (AYTU) over the last 15 years, with Jun 2025 value amounting to $620,000.

  • Aytu Biopharma's Net Income rose 415.75% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 195.99%. This contributed to the annual value of $620,000 for FY2025, which is 118.65% up from last year.
  • As of FY2025, Aytu Biopharma's Net Income stood at $620,000, which was up 118.65% from -$3.3 million recorded in FY2024.
  • Aytu Biopharma's Net Income's 5-year high stood at $620,000 during FY2025, with a 5-year trough of -$108.8 million in FY2022.
  • For the 3-year period, Aytu Biopharma's Net Income averaged around -$6.6 million, with its median value being -$3.3 million (2024).
  • In the last 5 years, Aytu Biopharma's Net Income tumbled by 327.93% in 2021 and then surged by 118.65% in 2025.
  • Yearly analysis of 5 years shows Aytu Biopharma's Net Income stood at -$58.3 million in 2021, then slumped by 86.62% to -$108.8 million in 2022, then soared by 84.21% to -$17.2 million in 2023, then skyrocketed by 80.65% to -$3.3 million in 2024, then surged by 118.65% to $620,000 in 2025.